Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in

Status Withdrawn

Clinical Trial Summary

This study evaluates the safety and efficacy of administering sorafenib concurrent with yttrium-90 radioembolization to patients with advanced hepatocellular cancer.

Clinical Trial Description

Studies in Asia of unresectable hepatocellular cancer (HCC) demonstrated that sorafenib could be administered safely at 400mg twice a day (BID) when initiated 14 days following radioembolization (RE). However, the ideal sequence of RE and sorafenib may not be completely elucidated, the two treatments given concurrently may be more effective than the sequential approach studied in the Asian trials. Preclinical models have demonstrated that sorafenib acts synergistically with radiation, increasing apoptosis. Furthermore, case reports suggest profound responses in patients who have received sorafenib concurrent with transarterial radioembolizatoin (TARE) as evidenced by improvement in symptoms, >80% decrease in alpha fetoprotein (AFP), and conversion from unresectable to resectable. Sorafenib concurrent with TARE may take advantage of the synergistic relationship between the two therapies and prove to be a more effective treatment strategy than sequential administration of TARE and sorafenib. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02288507
Study type	Interventional
Source	University of Hawaii
Contact
Status	Withdrawn
Phase	Phase 1
Start date	November 2014
Completion date	August 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03971201` - A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion	Phase 2
Recruiting	`NCT05489250` - The PLATON Network
Recruiting	`NCT04484636` - PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)	N/A
Completed	`NCT01967823` - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer	Phase 2
Terminated	`NCT00878215` - Clinical Application of Image-Guided Liver Surgery	Phase 2
Completed	`NCT04212286` - Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC	N/A
Recruiting	`NCT05992220` - Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion	Phase 2
Completed	`NCT02073435` - A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
Active, not recruiting	`NCT01522937` - A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer	Phase 2
Terminated	`NCT05061537` - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT04166240` - Measuring and Improving the Safety of Test Result Follow-Up	N/A
Terminated	`NCT03026803` - A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer	Phase 2
Active, not recruiting	`NCT04682847` - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Recruiting	`NCT05100082` - Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
Active, not recruiting	`NCT03195699` - Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers	Phase 1
Completed	`NCT02616692` - HCC Patient Preferences in Japan	N/A
Active, not recruiting	`NCT03132792` - AFPᶜ³³²T in Advanced HCC	Phase 1
Not yet recruiting	`NCT06239194` - Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT01849588` - Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C	Phase 4
Suspended	`NCT00909558` - Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer	Phase 1

Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms